Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$110.30M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$109.14M
Gross Margin
11.17%
TTM Avg
22.02%
3Y Avg
17.41%
5Y Avg
13.61%
Market Cap
$112.57M
Gross Margin
67.34%
TTM Avg
64.03%
3Y Avg
72.89%
5Y Avg
33.80%
Market Cap
$112.94M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
33.33%
Market Cap
$107.17M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
Market Cap
$107.09M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
2.35%
Market Cap
$106.98M
Gross Margin
83.37%
TTM Avg
83.81%
3Y Avg
82.64%
5Y Avg
80.50%
Market Cap
$106.96M
Gross Margin
46.49%
TTM Avg
23.25%
3Y Avg
11.62%
5Y Avg
7.75%
Market Cap
$106.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $110.30M | 0.00% | 0.00% | 0.00% | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | 11.17% | 22.02% | 17.41% | 13.61% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | 67.34% | 64.03% | 72.89% | 33.80% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | 0.00% | 0.00% | 50.00% | 33.33% |
| Apyx Medical Corporation (APYX)vs › | $107.17M | 33.94% | 48.53% | 56.75% | 59.91% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | 0.00% | 0.00% | 0.00% | 2.35% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | 83.37% | 83.81% | 82.64% | 80.50% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | 46.49% | 23.25% | 11.62% | 7.75% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | 99.91% | -67.10% | -31.47% | -20.98% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
